DeepLife
Kevin Carvalho is an experienced professional in drug discovery, strategic partnerships, and scientific consultancy with a strong focus on oncology and biophysics. Currently serving as the Head of Strategic Partnerships at DeepLife, Kevin has led initiatives in EU consortia aimed at tackling Taupathies and Pancreatic cancer, and has fostered collaborations with hospitals, universities, and research centers. Previous roles include Alliance Manager at DeepLife, Partnership Manager in Onco-Hematology at Institut Carnot CALYM, and Scientific Consultant at KeyCo Innovation, among others. Kevin holds a Doctorate in molecular biophysics and biochemistry from the University of Montpellier and has a robust background in research and development, particularly in innovative drug formulations and cellular technology.
This person is not in any teams
DeepLife
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.